Trials / Completed
CompletedNCT02759861
Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics
A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- University of Nebraska · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy and safety of Harvoni in treatment-naïve alcoholic subjects with Genotype 1 HCV infection
Detailed description
determine the cure rate of Harvoni in treatment naïve alcoholic subjects with Genotype 1 HCV infection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | harvoni | 8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2020-08-01
- Completion
- 2020-10-01
- First posted
- 2016-05-03
- Last updated
- 2023-12-29
- Results posted
- 2023-02-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02759861. Inclusion in this directory is not an endorsement.